Flexion Therapeutics, Inc. (FLXN)
(Delayed Data from NSDQ)
$10.77 USD
+0.10 (0.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.77 USD
+0.10 (0.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 0.99% and 15.58%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Flexion Therapeutics (FLXN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Flexion Therapeutics (FLXN) stock based on the movements in the options market lately.
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Flexion Therapeutics, Inc. (FLXN) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Flexion Therapeutics, Inc. (FLXN).
Flexion Therapeutics (FLXN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 9.43% and 20.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Flexion Therapeutics (FLXN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion Therapeutics (FLXN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 3.54% and -4.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion Starts Phase III Enrollment on Zilretta for Hip OA
by Zacks Equity Research
Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.
Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 7.26% and 17.84%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Flexion Therapeutics (FLXN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 4.92% and -4.12%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Why Flexion Therapeutics (FLXN) Could Be Positioned for a Slump
by Zacks Equity Research
Flexion Therapeutics (FLXN) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Flexion's (FLXN) Zilretta Therapy to Fast Capture OA Market
by Zacks Equity Research
Flexion's (FLXN) commercial launch of Zilretta seems well-timed keeping in view how rapidly the osteoarthritis market is growing worldwide.
Flexion's Zilretta Gets FDA Approval for Knee Pain, Stock Up
by Zacks Equity Research
Flexion Therapeutics (FLXN) announced that its non-opioid intra-articular injection for treating knee pain has received FDA approval.
Flexion Therapeutics (FLXN) in Focus: Stock Moves 10.4% Higher
by Zacks Equity Research
Flexion Therapeutics (FLXN) shares rose more than 10% in the last trading session, amid huge volumes.
Implied Volatility Surging for Flexion Therapeutics (FLXN) Stock Options
by Zacks Equity Research
Surging implied volatility makes Flexion Therapeutics (FLXN) Stock lucrative to the option traders.
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics
Flexion (FLXN) Stock Soars 35% on $1 Billion Sanofi Buyout
by Joseph Lu
Shares of Flexion Therapeutics (FLXN) soared on Thursday, up 36% to $26.80 per share following reports that French drug giant Sanofi (SNY) is in talks to purchase the biotech company for more than $1 billion in cash.
Top Momentum Stocks for the Week - (FLXN) (KBR)
by David Bartosiak
Momentum Stock Strategist David Bartosiak discusses this week's top momentum stocks, Flexion Therapeutics and KBR Inc.